Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -236.95% is 43% above its 3-year average of -414.98%, near the high end of its 3-year range (-4958.83%–-18.12%).
6.65% above its 12-month average of -253.84%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -246.71%.
NET PROFIT MARGIN
-236.95%
NET PROFIT MARGIN AVG TTM
-253.84%
NET PROFIT MARGIN AVG 3Y
-363.08%
NET PROFIT MARGIN AVG 5Y
N/A
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+6.65%
CURRENT VS 3Y AVG
+34.74%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 750 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
GRAIL Inc.
Market Cap
$6.01B
Net Profit Margin
-236.95%
TTM Avg
-253.84%
3Y Avg
-363.08%
5Y Avg
N/A
Market Cap
$5.91B
Net Profit Margin
67.88%
TTM Avg
22.01%
3Y Avg
16.68%
5Y Avg
14.76%
Market Cap
$5.90B
Net Profit Margin
-89.09%
TTM Avg
-187.61%
3Y Avg
-9430.16%
5Y Avg
-6286.77%
Market Cap
$5.74B
Net Profit Margin
9.59%
TTM Avg
-0.75%
3Y Avg
21.75%
5Y Avg
-53.79%
Market Cap
$5.68B
Net Profit Margin
-3602.68%
TTM Avg
-5857.26%
3Y Avg
-13524.50%
5Y Avg
-10844.39%
Market Cap
$6.33B
Net Profit Margin
-85.59%
TTM Avg
-151.92%
3Y Avg
-327.14%
5Y Avg
-585.95%
Market Cap
$5.54B
Net Profit Margin
-10.21%
TTM Avg
-9.94%
3Y Avg
-7.18%
5Y Avg
-7.18%
Market Cap
$6.51B
Net Profit Margin
17.69%
TTM Avg
17.76%
3Y Avg
15.93%
5Y Avg
7.17%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GRAIL Inc. (GRAL) | $6.01B | -236.95% | -253.84% | -363.08% | N/A |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.91B | 67.88% | 22.01% | 16.68% | 14.76% |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.90B | -89.09% | -187.61% | -9430.16% | -6286.77% |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.74B | 9.59% | -0.75% | 21.75% | -53.79% |
| CG Oncology Inc. (CGON)vs › | $5.68B | -3602.68% | -5857.26% | -13524.50% | -10844.39% |
| Rhythm Pharmaceuticals, Inc. (RYTM)vs › | $6.33B | -85.59% | -151.92% | -327.14% | -585.95% |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.54B | -10.21% | -9.94% | -7.18% | -7.18% |
| RadNet, Inc. (RDNT)vs › | $5.52B | -0.93% | -0.38% | 0.04% | 0.11% |
| Lantheus Holdings, Inc. (LNTH)vs › | $6.51B | 17.69% | 17.76% | 15.93% | 7.17% |
| Amneal Pharmaceuticals, Inc. (AMRX)vs › | $6.52B | 5.05% | -0.89% | -2.79% | -1.02% |
Operating Margin
-362.9%
Net Profit Margin
-236.9%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -246.71% |
| 2026-03-31 | -228.48% |
| 2025-12-31 | -227.48% |
| 2025-09-30 | -245.83% |
| 2025-06-30 | -320.69% |
| 2025-03-31 | -333.61% |
| 2024-12-31 | -253.75% |
| 2024-09-30 | -438.67% |
| 2024-06-30 | -4958.83% |
| 2024-03-31 | -819.26% |
| 2023-12-31 | -18.12% |
| 2023-09-30 | -4301.94% |
| 2023-06-30 | -861.27% |
| 2023-04-02 | -985.93% |
